Control of colon cancer development and progression by selected estrogen receptors modulators

Expert Review of Endocrinology and Metabolism

Volumn 3, Issue 4, 2008, Pages 503-511

  Martineti, Valentina ^a   Silvestri, Sandra ^b   Tonelli, Francesco ^a   Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Eli Lilly Italia SpA   (Italy)

Author keywords

17 estradiol; Colorectal cancer; Colorectal cancer cell; Estrogen receptor; Estrogen receptor agonist; Raloxifence; Selective estrogen receptor modulator; Tamoxifen

Indexed keywords

17 EPIESTRIOL; ALITRETINOIN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; APC PROTEIN; ARZOXIFENE; BAZEDOXIFENE; CELECOXIB; CIPROFLOXACIN; ESTRADIOL; ESTROGEN RECEPTOR BETA AGONIST; INTERMEDIN; LASOFOXIFENE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PRASTERONE; PROTEIN MLH1; QUERCETIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER PREVENTION; CARCINOGENESIS; CLINICAL TRIAL; COLON CANCER; COLORECTAL CARCINOGENESIS; DRUG BINDING; DRUG STRUCTURE; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; INTESTINE MUCOSA; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RECTUM MUCOSA; REVIEW; VERTEBRA FRACTURE;

EID: 55649086835     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.3.4.503     Document Type: Review

References (83)

1. Mandalà M, Mosconi S, Quadri A et al. Neoadjuvant chemotherapy for patients with liver metastasis from colorectal cancer. Expert Rev. Anticancer. Ther. 7(6), 887-897 (2007).
2. Bishop JM. Molecular themes in oncogenesis. Cell 64(2), 235-248 (1991).
3. Ponder BA. Molecular genetics of cancer. BMJ 304(6836), 1234-1236 (1992).
4. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal tumor development. N. Engl. J. Med. 319(9), 525-532 (1988).
5. Fearon ER, Cho KR, Nigro JM et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247(4938), 49-56 (1990).
6. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386(6627), 761-763 (1997).
7. Bodmer WF, Bailey CJ, Bodmer J et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328(6131), 614-616 (1987).
8. Al-Tassan N, Chmiel NH, Maynard J et al. Inherited variants of MYH associated with somatic G:C ->T:A mutation in colorectal tumors. Nat. Genet. 30(2), 227-332 (2002).
9. Peltomaki P, Aaltonene L, Sistonen P et al. Genetic mapping of a locus predisponing to human colorectal cancer. Science 260(5109), 810-812 (1993).
10. Quehenberger F, Vasen HFA, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J. Med. Genet. 42(6), 491-496 (2005).
11. Vasen HFA, Stormorken A, Menko FH et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J. Clin. Oncol. 19, 4074-4080 (2001).
12. Aarnio M, Mecklin JP, Aaltonen LA et al. Lifetime risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int. J. Cancer 64, 430-433 (1995).
13. Aarnio M, Sankila R, Pukkala E et al. Cancer risk in mutation carriers of DNA mismatch-repair genes. Int. J. Cancer 81, 214-218 (1999).
14. Parc Y, Boisson C, Thomas G et al. Cancer risk in 348 French MSH2 or MLH1 gene carriers. J. Med. Genet. 40, 208-213 (2003).
15. Watson P, Lynch HT. Cancer risk in mismatch repair gene mutation carriers. Fam. Cancer 1, 57-60 (2001).
16. Hendriks YM, de Jong AE, Morreau H et al. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J. Clin. 56(4), 213-225 (2006).
17. McMichael AJ, Potter JD. Do intrinsic sex differences in lower alimentary tract physiology influence the sex-specific risks of bowel cancer and other biliary and intestinal diseases? Am. J. Epidemiol. 118(5), 620-627 (1983).
18. Weiss NS, Daling JR, Chow WH. Incidence of cancer of the large bowel in women in relation to reproductive and hormonal factors. J. Natl Cancer Inst. 67(1), 57-60 (1981).
19. Grodstein F, Martinez ME, Platz EA et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann. Intern. Med. 128(9), 705-712 (1998).
20. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am. J. Med. 106(5), 574-582 (1999).
21. Chlebowski RT, Wactawaski-Wende J, Ritenbaugh C et al. Estrogens plus progestin and colorectal cancer in postmenopausal women. N. Engl. J. Med. 350(10), 991-1004 (2004).
22. Mandelson MT, Miglioretti D, Newcomb PA, Harrison R, Potter JD. Hormone replacement therapy in relation to survival in women diagnosed with colon cancer. Cancer Causes Control 14(10), 979-984 (2003).
23. Slattery ML, Potter JD, Curtin K et al. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res. 61(1), 126-130 (2001).
24. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J. Natl Cancer Inst. 90(11), 814-823 (1998).
25. Koehler KF, Helguero LA, Haldosén LA, Warner M, Gustafsson JA. Reflections on the discovery and significance of estrogen receptor β. Endocr. Rev. 26(3), 465-478 (2005).
26. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul PW. ERβ has nongenomic action in caveolae. Mol. Endocrinol. 16(5), 938-946 (2002).
27. Razandi M, Pedram A, Merchenthaler I, Greene GL, Levin ER. Plasma membrane estrogen receptors exist and functions as dimers. Mol. Endocrinol. 18(12), 2854-2865 (2004).
28. Acconcia F, Kumar R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett. 238(1), 1-14 (2006).
29. Nilsson S, Mäkelä S, Treuter E et al. Mechanisms of estrogen action. Physiol. Rev. 81(4), 1535-1565 (2001).
30. Pettersson K, Gustafsson JA. Role of estrogen receptor β in estrogen action. Ann. Rev. Physiol. 63, 165-192 (2001).
31. Couse JF, Korach KS. Estrogen receptor null mice. What have we learned and where will they lead us? Endocr. Rev. 20(3), 358-417 (1999).
32. X6ie LQ, Yu JP, Luo HS. Expression of estrogen receptor β in human colorectal cancer. World J. Gastroenterol. 10(2), 214-217 (2004).
33. Konstantinopoulos PA, Kominea A, Vandoros G et al. Oestrogen receptor β (ERβ) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur. J. Cancer 39(9), 1251-1258 (2003).
34. Jassam N, Bell SM, Speirs V, Quirke P. Loss of expression of estrogen receptor β in colon cancer and its association with Duke's staging. Oncol. Rep. 14(1), 17-21 (2005).
35. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Functional estrogen receptor β in colon cancer cells. Biochem. Biophys. Res. Commun. 261(2), 521-527 (1999).
36. Arai N, Strom A, Rafter JJ, Gustafsson JA. Estrogen receptor β mRNA in colon cancer cells: growth effects of estrogen and genistein. Biochem. Biophys. Res. Commun. 270(2), 425-431 (2000).
37. Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERβ isoforms in colon cancer. Cancer Res. 61(2), 632-640 (2001).
38. Nakayama Y, Sakamoto H, Satoh K, Yamamoto T. Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor β mediated system. Cancer Lett. 161(1), 63-71 (2000).
39. Nojima D, Li LC, Dharia A et al. CpG hypermethylation of the promoter region inactivates the estrogen receptor-β gene in patients with prostate carcinoma. Cancer 92(8), 2076-2083 (2001).
40. Zhao C, Lam EW, Sunters A et al. Expression of estrogen receptor β isoform in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 22(48), 7600-7606 (2003).
41. Zhang X, Leung YK, Ho SM. AP-2 regulates the transcription of estrogen receptor (ER)-β by acting through a methylation hotspot of the 0N promoter in prostate cancer cells. Oncogene 26(52), 7346-7354 (2007).
42. Liu MM, Albanese C, Anderson CM et al. Opposing action of estrogen receptors alpha and β on cyclin D1 gene expression. J. Biol. Chem. 277(27), 24353-24360 (2002).
43. Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor β acts as a dominant regulator of estrogen signaling. Oncogene 19(43), 4970-4978 (2000).
44. Weihua Z, Makela S, Andersson LC et al. A role for estrogen receptor β in the regulation of growth of the ventral prostate. Proc. Natl Acad. Sci. USA 98(11), 6330-6335 (2001).
45. Paech K, Webb P, Kuiper GG et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277(5331), 1508-1510 (1997).
46. Martineti V, Picariello L, Tognarini I et al. ERβ is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr. Relat. Cancer 12(2), 455-469 (2005).
47. Wada-Hiraike O, Imamov O, Hiraike H et al. Role of estrogen receptor β in colonic epithelium. Proc. Natl Acad. Sci. USA 103(8), 2959-2964 (2006).
48. Narayan S, Rajakumar G, Prouix H, Singh P. Estradiol is trophic for colon cancer in mice: effect on ornithine decarboxylase and c-myc messenger RNA. Gastroenterology 103(6), 1823-1832 (1992).
49. Singh S, Paraskeva C, Gallimore PH, Sheppard MC, Langman MJ. Differential growth response to oestrogen of premalignant and malignant colonic cell lines. Anti Cancer Res. 14(3A), 1037-1041 (1994).
50. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Functional estrogen receptor β in colon cancer cells. Biochem. Biophys. Res. Commun. 261(2), 521-527 (1999).
51. Weyant MJ, Carothers AM, Mahmoud NN et al. Reciprocal expression of ERα and ERβ is associated with estrogen-mediated modulation of intestinal tumorigenesis. Cancer Res. 61(6), 2547-2551 (2001).
52. Hsu HH, Cheng SF, Wu CC et al. Apoptotic effects of over-expressed estrogen receptor-β on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner. China J. Physiol. 49(2), 110-116 (2006).
53. Lee H, Jiang F, Wang Q et al. MEKK1 activation of human estrogen receptor β and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Mol. Endocrinol. 14(11), 1882-1896 (2000).
54. Driggers PH, Segars JH, Rubino DM. The protooncoprotein Brx activates estrogen receptor β by a p38 mitogen-activated protein kinase pathway. J. Biol. Chem. 276(50), 46792-46797 (2001).
55. Chen SL, Chang YJ, Wu YH, Lin KH. Mitogenactivated protein kinases potentiate thyroid hormone receptor transcriptional activity by stabilizing its protein. Endocrinology 144(4), 1407-1419 (2003).
56. Lee H, Bai W. Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol. Cell. Biol. 22(16), 5835-5845 (2002).
57. Wilpart M, Mainguet P, Maskens A, Roberfroid M. Mutagenicity of 1,2-dimethylhydrazine towards Salmonella typhimurium, co-mutagenic effect of secondary biliary acids. Carcinogenesis 4(1), 45-48 (1983).
58. Allende HD, Ona FV, Davis HT. Gallbladder disease: risk factor for colorectal carcinoma? J. Clin. Gastroenterol. 6(1), 51-55 (1984).
59. McMichael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J. Natl Cancer Inst. 65(6), 1201-1207 (1980).
60. Terry PD, Miller AB, Rohan TE. Obesity and colorectal cancer risk in women. Gut 51(2), 191-194 (2002).
61. Powell DR, Suwanichkul A, Cubbage ML, DePaolis LA, Snuggs MB, Lee PD. Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. J. Biol. Chem. 266(28), 18868-18876 (1991).
62. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J. Nutr. 131(Suppl. 11), S3109-S3120 (2001).
63. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7), 637-645 (1999).
64. Kanis JA, Johnell O, Black DM et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 33(3), 293-300 (2003).
65. Siris ES, Harris ST, Eastell R et al. Continuing Outcomes Relevant to Evista (CORE) Investigators. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J. Bone Miner. Res. 20(9), 1514-1524 (2005).
66. Cauley JA, Norton L, Lippman ME et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat. 65(2), 125-134 (2001).
67. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281(23), 2189-2197 (1999).
68. Martino S, Cauley JA, Barrett-Connor E et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl Cancer Inst. 96(23), 1751-1761 (2004).
69. Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23), 2727-2741 (2006).
70. Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA; Multiple Outcomes of Raloxifene Evaluation (MORE) Trial. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287(2), 216-220 (2002).
71. Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ. Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J. Bone Miner. Res. 19(8), 1270-1275 (2004).
72. Dickler MN, Norton L. The MORE trial: multiple outcomes for raloxifene evaluation - breast cancer as a secondary end point: implications for prevention. Ann. NY Acad. Sci. 949, 134-142 (2001).
73. Barrett-Connor E, Mosca L, Collins P et al. Raloxifene Use for The Heart (RUTH) trial investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355(2), 125-137 (2006).
74. Picariello L, Fiorelli G, Martineti V et al. Growth response of colon cancer cell lines to selective estrogen receptor modulators. Anti Cancer Res. 23(3B), 2419-2424 (2003).
75. Kuiper GG, Lemmen JG, Carlsson B et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139(10), 4252-4263 (1998).
76. Herold C, Ganslmayer M, Ocker M et al. Overadditive anti-proliferative and proapoptotic effects of a combination therapy on colorectal carcinoma cells. Int. J. Oncol. 23(3), 751-756 (2003).
77. Walsh JME, Cheung AM, Yang D, Litwack S, Grady D. Raloxifene and colorectal cancer. J. Womens Health (Larchmt). 14(4), 299-305 (2005).
78. Yin F, Shi YQ, Chen CP et al. Expression of cDNA fragment encoding MGr1-Ag1 detected by MDR related antibody MGr1 in gastric cancer. Shi Jie Hua Ren Xiao Hua Ze Zhi 11, 18-21 (2003).
79. Uchiyama-Kokubu N, Watanabe T. Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance. Anticancer Drugs 12(9), 769-779 (2001).
80. Wang BL, Zhai HY, Chen BY et al. Clinical relationship between MDR1 gene and gallbladder cancer. Hepatobiliary Pancreat. Dis. Int. 3(2), 296-299 (2004).
81. Lorke DE, Kruger M, Buchert R, Bohuslavizki KH, Clausen M, Schumacher U. In vitro and in vivo tracer characteristics of an established multidrug-resistant human colon cancer cell line. J. Nucl. Med. 42(4), 646-654 (2001).
82. Shen LZ, Hua YB, Yu XM et al. Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo. World J. Gastroenterol. 11(7), 1060-1064 (2005).
83. Hamilton G, Cosentini EP, Teleky B et al. The multidrugs-resistance modifiers verapamil, cyclosporine A and tamoxifen induce an intracellular acidification in colon carcinoma cell lines in vitro. Anti Cancer Res. 13(6A), 2059-2063 (1993).